Bausch Health Companies Inc. announced that its Solta Medical unit has completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. on December 1 2025. The deal, which was not disclosed in financial terms, brings a long‑time distribution partner into Solta’s direct control and expands the company’s footprint in China’s rapidly growing medical‑aesthetics market.
Solta Medical’s performance in the third quarter of 2025 underscored the strategic value of the transaction. Revenue reached $140 million, up 25% year‑over‑year, while the fourth quarter of 2024 saw $138 million, a 34% increase on a reported basis. The growth was driven largely by strong demand in South Korea and China, where the company’s Thermage and other aesthetic devices have gained traction.
The acquisition is designed to leverage Shibo’s established local expertise, technology platform, and distribution network. By integrating Shibo’s operations, Solta Medical will gain immediate access to a broader customer base, improve service delivery, and accelerate sales of its high‑margin aesthetic devices. The move aligns with the broader trend of a Chinese medical‑aesthetics market projected to reach $4.12 billion by 2035, growing at a CAGR of 8.92% from 2024 to 2035.
Management highlighted the strategic fit of the deal. CEO Thomas J. Appio said the acquisition “expands Solta Medical’s geographical reach and market scale in China” and that the company can “immediately gain access to a large customer base to drive future revenue and market share growth.” Senior Vice President Jiny Kim noted that Shibo has been “integral to the success of Thermage in China for more than a decade” and that the integration will “build on that trust and deliver even greater value.”
The announcement was well received by investors, reflecting confidence in Bausch Health’s growth strategy and its focus on high‑growth international markets. The company’s Q3 2025 results, which included raised full‑year guidance, further reinforced the positive outlook for Solta Medical’s expansion in China.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.